The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Ropes & Gray LLP

Work +1 617 951 7000
Boston, Central Hong Kong, Chicago, East Palo Alto, London EC4A, London EC4M and 6 more

Mark Bellomy

Ropes & Gray LLP


Mark advises a wide range of companies, investors and institutions in intellectual property and corporate matters. His practice focuses primarily on technology-based corporate transactions, including licensing, research and development collaborations, strategic commercial partnerships, mergers and acquisitions, information-technology outsourcing, joint ventures, technology transfers, product development, supply and distribution relationships and corporate finance transactions. He also provides clients with strategic advice regarding the creation and management of intellectual property assets and day-to-day commercial and corporate matters. Mark is a patent attorney registered with the United States Patent and Trademark Office, and has experience prosecuting patent applications relating to software, electromechanical devices and consumer goods. Prior to attending law school, Mark served as a cavalry officer and scout platoon leader in the United States Army. Mark has also served as in-house counsel for one of the world's leading pharmaceutical companies.

United States: Industry focus

Healthcare: life sciences

Within: Healthcare: life sciences

Ropes & Gray LLP’s team often advises clients on high-profile corporate and litigation matters. Co-chair Gregory Levine, along with Zach Blume and Paul Kinsella, led advice to Aegerion Pharmaceuticals on various contentious and non-contentious issues, including the negotiation of a consent decree with the FDA and DOJ. Michael Beauvais assisted Bain Capital with a $55m financing and investment round for German biopharmaceutical company InflaRx. David McIntosh acted for Akebia Therapeutics on various corporate transactions, including a number of major licensing agreements. The team, which includes the well-regarded Steven Wilcox, Mark Bellomy and Marc Rubenstein, was bolstered by the arrivals of Paul Scrivano in San Francisco from O'Melveny & Myers LLP and David Blittner in New York from Weil, Gotshal & Manges LLP. All partners are based in Washington DC and Boston unless otherwise stated.

[back to top]

United States: Intellectual property

Patents: licensing

Within: Patents: licensing

Ropes & Gray LLP is active in the pharmaceutical, life sciences and technology sectors. The firm’s main presence is in Boston where practice head David McIntosh and Mark Bellomy are based. Silicon Valley’s Megan Baca is also noted. A major highlight was assisting Akebia Therapeutics with its $1bn collaboration licence agreement with Otsuka Pharmaceutical for the development and commercialisation of an aenemia drug treatment, one of several strategic licence agreements that the client entrusted the practice with. In other work, Edward Black led in advising investment managing firm Tudor Investment on a collaboration agreement with an engineering firm in the field of artificial intelligence to advance trading strategies. Other clients include AMAG Pharmaceuticals, Lantheus Holdings and TPG Capital. James McGraw joined Gray Reed.

[back to top]

United States: M&A/corporate and commercial

Commercial deals and contracts

Within: Commercial deals and contracts

Known for its life sciences expertise, Ropes & Gray LLP’s practice handles a wide range of licensing and commercial agreements. Practice head Edward Black led advice to Tudor Investment Corporation on various IP transactions, including drafting agreements regarding a collaboration with an engineering firm. The group acted for Bain Capital Private Equity in all aspects arising from its acquisition of Innocor from a Sun Capital Partners affiliate. Mark Bellomy was engaged by Sarepta Therapuetics on the company’s sponsored research and option agreement with Généthon. David McIntosh and Silicon Valley-based Megan Baca are key names. All other partners are based in Boston. Other clients include Akebia Therapuetics, Pfizer and Juno Therapeutics.

[back to top]

Back to index

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to